Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Precision cancer medicine: Concepts, current practice, and future developments.
Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J, Ott PA, von Deimling A, Fröhling S, Voest E, Klauschen F, Dienstmann R, Alshibany A, Siu LL, Stenzinger A. Edsjö A, et al. Among authors: ott pa. J Intern Med. 2023 Oct;294(4):455-481. doi: 10.1111/joim.13709. Epub 2023 Aug 28. J Intern Med. 2023. PMID: 37641393 Review.
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert L, Thielemans K, Feldman SA, van der Burg SH, Bogaert C, Ott PA. Lybaert L, et al. Among authors: ott pa. Trends Cancer. 2023 Jun;9(6):503-519. doi: 10.1016/j.trecan.2023.02.004. Epub 2023 Apr 11. Trends Cancer. 2023. PMID: 37055237 Free PMC article. Review.
Challenges in neoantigen-directed therapeutics.
Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Lybaert L, et al. Among authors: ott pa. Cancer Cell. 2023 Jan 9;41(1):15-40. doi: 10.1016/j.ccell.2022.10.013. Epub 2022 Nov 10. Cancer Cell. 2023. PMID: 36368320 Free article. Review.
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Khaddour K, Haq R, Buchbinder EI, Liu D, Manos MP, Ott PA, Hodi FS, Insco ML. Khaddour K, et al. Among authors: ott pa. Oncologist. 2024 Nov 6:oyae297. doi: 10.1093/oncolo/oyae297. Online ahead of print. Oncologist. 2024. PMID: 39504576 Free article.
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
Maloney AK, Giobbie-Hurder A, Katukota N, Fogarasi MC, Ott PA, Hodi FS, Sussman TA, Silk AW, Haq R, Liu D, Insco M, Buchbinder EI. Maloney AK, et al. Among authors: ott pa. J Immunother Cancer. 2024 Aug 28;12(8):e009061. doi: 10.1136/jitc-2024-009061. J Immunother Cancer. 2024. PMID: 39209453 Free PMC article.
Advances in Vaccines for Melanoma.
Cui C, Ott PA, Wu CJ. Cui C, et al. Among authors: ott pa. Hematol Oncol Clin North Am. 2024 Oct;38(5):1045-1060. doi: 10.1016/j.hoc.2024.05.009. Epub 2024 Jul 29. Hematol Oncol Clin North Am. 2024. PMID: 39079791 Review.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland G, Chandra S, Chmielowski B, DiMaio D, Dronca R, Fields RC, Fleming MD, Galan A, Guild S, Hyngstrom J, Karakousis G, Kendra K, Kiuru M, Lange JR, Lanning R, Logan T, Olson D, Olszanski AJ, Ott PA, Ross MI, Rothermel L, Salama AK, Sharma R, Skitzki J, Smith E, Tsai K, Wuthrick E, Xing Y, McMillian N, Espinosa S. Swetter SM, et al. Among authors: ott pa. J Natl Compr Canc Netw. 2024 Jul;22(5):290-298. doi: 10.6004/jnccn.2024.0036. J Natl Compr Canc Netw. 2024. PMID: 39019054
180 results